Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT04679012RecruitingPhase 2
Polatuzumab plus chemotherapy for Richter’s transformation
This trial studies whether polatuzumab added to chemotherapy can improve outcomes in people whose CLL/SLL has transformed into a type of aggressive lymphoma called DLBCL. It may help shrink tumors and control the disease after this transformation.
New York, New YorkAges 18 years+ - NCT04684147RecruitingPhase 2
CNCT19 cell therapy for relapsed or refractory ALL
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
Beijing, Beijing MunicipalityAges 18–65 - NCT04684602RecruitingPhase 1/Phase 2
Study of stem cells for several short- and long-term illnesses
This early-stage study tests whether injections of mesenchymal stem cells can be safe and helpful for certain chronic (long-term) and acute (short-term) conditions. You might be considered if you can consent, are able to return for follow-up visits, and do not have key reasons that would make stem-cell treatment unsafe.
Culver City, CaliforniaAges 18 years+ - NCT04691622RecruitingPhase 1
Treat chronic norovirus using donor immune cells
This Phase 1 study tests whether giving immune cells made from a donor can help children and adults with long-lasting (chronic) norovirus infection. It’s aimed at people whose immune system is weakened after a stem cell transplant, solid organ transplant, or due to primary immune problems.
Washington D.C., District of ColumbiaAges 3 months–80 years - NCT04694534Recruiting
Serious game program to help thinking skills in multiple sclerosis
This trial tests whether a computer “serious game” can improve thinking and memory skills in people with multiple sclerosis (MS). It’s designed for adults who report thinking problems and show weaker-than-average results on specific brain tests.
Arras, Hauts-de-FranceAges 18–65 - NCT04698421Recruiting
Blood and tissue sample collection for rare autoimmune nerve diseases
This study collects biological samples (like blood or other specimens) from people with rare neurological conditions that may involve the immune system. Your samples may help researchers better understand these diseases.
ToulouseAges 6–99 - NCT04699747RecruitingPhase 1
MRI and PET scan study for multiple sclerosis brain changes
This Phase 1 study tests a special tracer used during MRI and PET scans to look at brain changes in people with multiple sclerosis. It’s mainly aimed at improving how these scans can detect disease-related changes and confirming the tracer works safely.
Boston, MassachusettsAges 18–65 - NCT04700579Recruiting
Study lung changes before and after treatment for active TB
This study looks at changes in the lungs and immune system before TB treatment and again after treatment. By sampling lung fluid and comparing it over time, researchers hope to learn signatures that reflect how TB responds to care.
Cape Town, Western CapeAges 18–60 - NCT04702256RecruitingPhase 3
Treating lupus kidney inflammation with or without extra steroid tablets
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
ParisAges 14 years+ - NCT04704323RecruitingPhase 1
CAP-100 drug study for hard-to-treat CLL after prior treatments
This early-phase (Phase 1) study tests CAP-100 in adults with CLL or SLL that has come back or did not respond to at least two previous treatments. The goal is to see how the drug works and whether it is safe enough to keep studying.
Boston, MassachusettsAges 18 years+ - NCT04706988Recruiting
Asthma study linking lung bacteria to asthma types
This study looks at the tiny germs in your airways (airway microbiota) to better understand different asthma “types” and what might drive symptoms. It may help researchers find more personalized approaches to asthma care by learning how lung bacteria relate to your asthma features.
ShatinAges 18 years+ - NCT04710576RecruitingPhase 2
Axatilimab for chronic graft-versus-host disease
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
Birmingham, AlabamaAges 2 years+ - NCT04707976Recruiting
Smart anal irrigation vs standard care for bowel issues in MS
This study compares a smart device for transanal irrigation with regular bowel care in people with multiple sclerosis (MS) who have ongoing bowel problems. It aims to see if the smart irrigation approach improves bowel control and reduces symptoms.
AarhusAges 18 years+ - NCT04711200RecruitingPhase 1/Phase 2
Study of special stem cells for severe skin peeling (SJS-TEN)
This early-phase trial tests stem-cell treatment to help people with severe skin reactions called SJS-TEN. It may reduce ongoing skin damage and help recovery when treatment is started soon after symptoms begin.
CréteilAges 18–75 - NCT04721717Recruiting
Workshop for healing writing after paralysis
This trial tests whether a structured writing workshop can help people living with paralysis and their ALS caregivers. It focuses on communication through words (spoken or written) to support well-being.
Birmingham, AlabamaAges 18 years+ - NCT04731831Recruiting
Testing how well TNF medicines work in inflammatory arthritis
This study looks at how your immune system responds to starting infliximab or adalimumab for rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Results may help doctors understand why some people don’t respond as well and how to improve treatment.
AalborgAges 18 years+ - NCT04745221Recruiting
Fecal microbes therapy to help prevent graft-versus-host disease
This trial studies a treatment made from donor gut microbes to help prevent a common complication after a transplant called acute graft-versus-host disease (aGVHD). It may help by improving the balance and variety of gut bacteria during recovery after haploidentical transplant.
Suzhou, JiangsuAges 18–60 - NCT04745728RecruitingPhase 3
Testing different immune-suppressing treatments for membranous kidney disease
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
Beijing, Beijing MunicipalityAges 18–80 - NCT04746209RecruitingPhase 2
Blinatumomab after transplant for high-risk B-ALL patients
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
Milwaukee, WisconsinAges Up to 25 years - NCT04747912RecruitingPhase 2
Chemotherapy-free early treatment for Ph+ ALL using inotuzumab
This Phase 2 trial tests a treatment strategy for newly diagnosed Ph+ B-cell acute lymphoblastic leukemia (ALL) that avoids traditional chemotherapy during the early “induction” phase, using inotuzumab ozogamicin instead. If it works, it could help control the leukemia while reducing exposure to chemotherapy early on.
Chicago, IllinoisAges 18 years+ - NCT04748809Recruiting
Diet trial for rheumatoid arthritis inflammation
This study tests whether an anti-inflammatory diet can help people with rheumatoid arthritis by lowering inflammation and disease activity. You may join if your symptoms are currently mild to moderate and you haven’t recently changed medications or your treatment plan.
La Jolla, CaliforniaAges 18 years+ - NCT04751760Recruiting
Test a new blood test for IgE allergy markers
This study checks whether a new blood test can measure allergy-related immune signals (IgE) in people with known or suspected allergies. If it works well, it could help doctors diagnose and track IgE allergies more easily.
ToulouseAges 6 months–99 years - NCT04751396Recruiting
Melanoma education for people with autoimmune conditions
This trial tests an educational tool to help people with melanoma and pre-existing autoimmune disease understand immune checkpoint inhibitor treatment. It aims to support you and your care team with information that can help you make decisions and feel more prepared.
Houston, TexasAges 18 years+ - NCT04752826RecruitingPhase 1/Phase 2
Testing BI-1808 plus Keytruda for advanced cancers
This trial tests a new cancer medicine (BI-1808) either alone or together with Keytruda (pembrolizumab) in people with advanced cancers. It may help by strengthening the immune system’s attack on cancer, especially if standard treatments are no longer working or aren’t suitable.
Duarte, CaliforniaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.